Donna S. Cox

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

Jeffrey R. Infante, Leslie A. Fecher, Gerald S. Falchook et al. · The Lancet Oncology · 2012 · 554 citations

Pharmacological Study, Efficacy Data, Pharmacology +7

The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers

Gary H. Kamimori, Chetan S. Karyekar, Ronald Otterstetter et al. · International Journal of Pharmaceutics · 2002 · 376 citations

Physiology, Oral Hygiene, Relative Bioavailability +2

Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies.

John Nemunaitis, C. J. Poole, John Primrose et al. · PubMed · 1998 · 213 citations

Pathology, Metronomic Chemotherapy, Tumor Biology +16

Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in <scp><i>RAS</i></scp>‐mutant relapsed or refractory myeloid malignancies

Gautam Borthakur, Leslie Popplewell, Michael Boyiadzis et al. · Cancer · 2016 · 139 citations · Full text

A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors

Anthony W. Tolcher, Johanna C. Bendell, Kyriakos P. Papadopoulos et al. · Annals of Oncology · 2014 · 124 citations · Full text

Medicine, Pharmacology, Phase Ib Trial +6